一种新的抑制HSV2复发的药物专利信息
来源：全球专利http://www.wipo.int/pctdb/en/wo.jsp?wo=2003089597
Selective inhibitors for COX-2 were discovered to prevent the reactivation of viruses that cause latent infections such as herpes simplex virus (HSV-1 and HSV-2). Using mice with a latent infection of HSV, which is subject to reactivation when heat-stressed, a selective COX-2 inhibitor (celecoxib ) was shown to significantly suppress viral reactivation in the eye when the inhibitor was administered either by intraperitoneal injection or orally. Acetylsalicylic acid, a nonspecific cyclooxygenase inhibitor, was also found to suppress viral reactivation in the heat-stressed mouse model. The COX-2 specific inhibitor, celecoxib, was more effective in preventing viral recurrence than was the nonspecific cyclooxygenase inhibitor aspirin. The use of selective inhibitors of COX-2 to inhibit the recurrence of latent viral infections will be more effective and have fewer side effects than the nonspecific inhibitors. In addition, selective inhibitors of COX-2 can be combined with other antiviral compounds。
为了方便不懂英文的患者的阅读理解，我将这个专利的摘要翻译如下：
发现单氨氧化酶2的选择性抑制剂能有效的抑制潜伏的HSV1和HSV2的复发。使用鼠的HSV潜伏感染模型，当热应激促发时，腹腔注射或者口服塞来昔布都能非常有效的抑制眼部的复发。乙酰水杨酸是一种非特异的单氨氧化酶2的抑制剂，也有抑制复发的作用。然而，塞来昔布比非反非特异的非特异的单氨氧化酶2的抑制剂阿司匹林能更为有效抑制复发而且付作用更小。此外，塞来昔布还可以和其他抗病毒药物组合使用。
附注：塞来昔布是美国FDA批准上市的药物，辉瑞公司的产品
声明：本文仅供参考，由于这种治疗新方法在我国绝大多数医院都还没有开始，许多医师都不了解这种治疗方法。
